Copy Link Print Information

Pumitamig

(別名: PM-8002; BNT-327)
カスタマーレビュー

Based on 1 Customer Validation

Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

  • 純度: 99.6%
  • 分子量:172.48 kDa
  • 保管条件:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Pumitamig
  • Experimental Validation Results for Pumitamig
  • Experimental Validation Results for Pumitamig
  • Experimental Validation Results for Pumitamig
  • Experimental Validation Results for Pumitamig
  • Pumitamig Chemical Structure
    Pumitamig 構造式
容量
価格（税別）
在庫状況
数量
Amount: USD 0.00
Please select quantity
or
or

* アイテムを追加する前、数量をご選択ください

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Pumitamig:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
最寄りの代理店をお探しください Your local distributor: Hycultec GmbHHycultec
  • 生物活性
  • 化学情報
  • 純度とドキュメンテーション
  • 参考文献
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

VEGFR アイソフォーム固有の製品をすべて表示

More
Keywords
MOQ
Minimum order quantity
100 mg

お問い合わせ 在庫あり

Other size
お問い合わせ
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress ログイン
Register
Sign in to MedChemExpress
新規会員登録

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    IgG1-kappa-VH

  • 1/16

    Immobilized hu-PD-L1-ECD-His can bind PM-8002. The EC50 for this effect is 116.7 ng/mL.

  • 1/16

    Immobilized rhVEGF can bind PM-8002. The EC50 for this effect is 19.39 ng/mL.

  • 1/16

    Flow Cytometry analysis of Hela cells labelling PD-1 (red) with Pumitamig (anti-PD-1) (HY-P991097). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99991, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

  • 1/16

    Flow Cytometry analysis of K562 cells labelling VEGF (red) with Pumitamig (HY-P991097). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

  • Pumitamig Chemical Structure
    1/16
  • Pumitamig
  • Immobilized hu-PD-L1-ECD-His can bind PM-8002. The EC50 for this effect is 116.7 ng/mL.
  • Immobilized rhVEGF can bind PM-8002. The EC50 for this effect is 19.39 ng/mL.
  • Flow Cytometry analysis of Hela cells labelling PD-1 (red) with Pumitamig (anti-PD-1) (HY-P991097). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99991, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
  • Flow Cytometry analysis of K562 cells labelling VEGF (red) with Pumitamig (HY-P991097). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
  • IgG1-kappa-VH